CRISPR Therapeutics AG
CRSPHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframePart of the healthcare sector, CRISPR Therapeutics AG (CRSP) is listed under Biotechnology. At a $5.42B market cap, CRISPR Therapeutics AG ranks as a mid-cap company within healthcare. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Market Cap
$5.42B
Beta
1.74
P/E (TTM)
—
P/E (Fwd)
-14.55
EPS (TTM)
$-6.17
EPS (Fwd)
$-3.86
ROE
-31.2%
ROA
-14.1%
Cash
$2.44B
Total Debt
$787.6M
Free CF
-$260.9M
52W Change
52.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $2.44B in cash comfortably exceeding the $787.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$260.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -31.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $436K (2022) to $0 (2025), a 100% decline worth watching.
A beta of 1.74 means CRSP is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CRSP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.